Intismeran autogene, a personalized messenger RNA (mRNA)-based cancer therapy developed by Moderna and Merck, improved recurrence-free survival and distant metastasis-free survival when added to pembrolizumab after surgery for high-risk melanoma, according to topline results from the Phase 3 INTerpath-001 trial announced on August 19, 2026. The randomized, double-blind study tested whether an individualized neoantigen therapy could add benefit to standard adjuvant anti-PD-1 treatment in patients with completely resected stage IIB through IV melanoma, but the companies have not yet released the Phase 3 hazard ratios, absolute event rates, or overall-survival results.
The Phase 3 trial tested whether a patient-specific therapy could prevent melanoma from returning
INTerpath-001 is a Phase 3 randomized, double-blind, placebo- and active-comparator-controlled trial registered as NCT05933577. It enrolled adults with high-risk cutaneous melanoma that had been completely removed surgically and compared intismeran autogene plus pembrolizumab with placebo plus pembrolizumab. Pembrolizumab, sold as Keytruda, is already approved as adjuvant treatment after resection for stage IIB, IIC, and III melanoma.
The study is testing treatment in the period after surgery, when no macroscopic tumor may remain but microscopic disease can still seed a recurrence. That setting is important in melanoma because recurrence risk can remain substantial even after apparently complete resection. The study’s primary endpoint is recurrence-free survival, which counts local, regional, or distant recurrence, a new primary melanoma, or death. Distant metastasis-free survival is a key secondary endpoint.
The trial represents a different use of mRNA technology from the preventive vaccines that made the platform widely familiar. Intismeran is not designed to prevent melanoma in healthy people. It is a therapeutic, individualized product made from information contained in a patient’s existing tumor.
The topline readout met both recurrence and distant-metastasis endpoints
Moderna and Merck said the combination produced a statistically significant improvement in recurrence-free survival compared with pembrolizumab alone and also met the key secondary endpoint of distant metastasis-free survival. Reuters reported that 1,137 patients were included in the late-stage study and that no new safety signal had emerged at the interim analysis.
Those results make INTerpath-001 the first positive Phase 3 readout reported for a personalized mRNA-based cancer therapy. The distinction matters because many cancer vaccines have generated measurable immune responses without establishing that those responses improve clinically meaningful outcomes in randomized late-stage trials.
What has not been disclosed is just as important as what has. The companies have not yet reported the hazard ratio for recurrence-free survival, the absolute proportion of patients who recurred in each group, the magnitude of the distant metastasis-free survival difference, or mature overall-survival data. They said detailed findings will be presented at a future medical meeting.
The treatment is built from the mutation profile of each patient’s tumor
Intismeran autogene is an individualized neoantigen therapy. After surgery, tumor tissue is sequenced to identify mutations that can generate abnormal peptide sequences, called neoantigens, that are present in cancer cells but absent from normal tissue. Computational selection is then used to choose up to 34 neoantigens for inclusion in a synthetic mRNA construct made specifically for that patient.
After administration, cells translate the mRNA instructions and process the encoded neoantigens for presentation to the immune system. The aim is to expand T-cell populations capable of recognizing tumor-specific targets. This is conceptually related to other efforts to train the immune system to recognize cancer, but the defining feature here is that the antigen set differs from patient to patient.
Pembrolizumab addresses a separate immune-control mechanism. It blocks programmed cell death protein 1 (PD-1), an inhibitory receptor on T cells that can suppress antitumor immune activity when engaged by its ligands. Pairing the two approaches is therefore biologically complementary: intismeran attempts to broaden and focus tumor-specific T-cell recognition, while pembrolizumab reduces an inhibitory signal that can limit those T cells after they encounter cancer.
Earlier randomized data suggested the effect can persist for at least five years
The rationale for the Phase 3 program came from the randomized Phase 2b KEYNOTE-942 study, which enrolled 157 patients with completely resected stage IIIB through IV melanoma. Participants were assigned 2:1 to intismeran plus pembrolizumab or pembrolizumab alone.
At a median planned follow-up of 60.3 months, the combination reduced the risk of recurrence or death by 49% compared with pembrolizumab alone, with a hazard ratio of 0.51 and a 95% confidence interval of 0.29 to 0.89. Five-year recurrence-free survival was 68.8% in the combination group and 49.1% with pembrolizumab alone.
Distant metastasis-free survival also favored the combination, with a 59% lower risk of distant metastasis or death and a hazard ratio of 0.41. Overall survival was exploratory and remained statistically uncertain: the hazard ratio was 0.47 with a wide 95% confidence interval of 0.17 to 1.35. Seven patients died in each treatment group, although the groups were different sizes because of the 2:1 randomization.
The five-year analysis also provided mechanistic evidence. Patients receiving the individualized therapy showed greater expansion of new T-cell clonotypes, and some of those clonotypes were linked to neoantigens encoded by intismeran. That does not by itself prove why the clinical effect occurred, but it is consistent with the intended mechanism of generating new tumor-specific immune responses.
The new Phase 3 result is stronger evidence, but its magnitude is still unknown
A positive randomized Phase 3 trial carries substantially more evidentiary weight than the earlier 157-patient Phase 2b study because it tests the strategy in a larger, blinded population and against an active standard-of-care comparator. It also broadens the population to include resected stage IIB and IIC disease, in addition to later-stage resected melanoma.
The phrase “met the primary endpoint,” however, does not tell clinicians or patients how large the benefit is. A statistically significant hazard ratio can correspond to a large or modest absolute difference depending on baseline recurrence risk, duration of follow-up, and the distribution of events over time. Those numbers will be needed to estimate how many patients would need treatment to prevent one recurrence and how the benefit varies by melanoma stage and other risk factors.
The Phase 2b safety profile offers some context but cannot substitute for the Phase 3 safety analysis. In the five-year Phase 2b report, the most common adverse events attributed to the combination included fatigue, injection-site pain, and chills. Immune-related adverse events occurred at similar frequencies in the combination and pembrolizumab-alone groups. The larger trial will be important for detecting less common toxicities and for clarifying discontinuation rates.
Manufacturing will determine whether a personalized therapy can scale
Unlike an off-the-shelf drug, intismeran requires a chain of patient-specific steps: tumor sampling, sequencing, computational neoantigen selection, individualized mRNA manufacturing, quality testing, and delivery back to the treating center. That workflow creates practical questions about turnaround time, manufacturing capacity, cost, and access that do not arise in the same way for conventional monoclonal antibodies.
Those constraints may become especially important if the approach expands into common cancers. Moderna and Merck are already evaluating intismeran in additional tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma. Positive melanoma data support the platform concept, but they do not establish efficacy in those diseases because tumor biology, mutation burden, recurrence patterns, and standard treatments differ.
The broader significance is that individualized cancer treatment is moving from molecular selection of an existing drug toward manufacturing a therapy from a patient’s own tumor sequence. That places intismeran at the intersection of cancer immunology, genomics, and genetic medicine, with a production model that is closer to a bespoke biologic than a conventional vaccine.
What the evidence cannot yet answer
The Phase 3 announcement does not yet establish how much recurrence risk falls in absolute terms, whether overall survival improves, which melanoma subgroups benefit most, or how long any additional protection lasts. It also does not show that the therapy works as a stand-alone treatment, because INTerpath-001 evaluates it on top of pembrolizumab.
The trial was conducted in patients whose melanoma had been completely resected, so the result should not be generalized to unresectable or widely metastatic disease. It is also not evidence that an mRNA vaccine prevents melanoma in people without cancer. Established prevention measures, including reducing ultraviolet exposure and using effective sun protection, address a different point in the disease pathway.
The companies have said they are discussing the data with regulators. Until the complete Phase 3 results are presented and reviewed, the most defensible conclusion is specific: adding a patient-specific mRNA neoantigen therapy to pembrolizumab improved both recurrence-free and distant metastasis-free survival in a randomized Phase 3 study of resected high-risk melanoma. The size, durability, safety trade-offs, and regulatory significance of that benefit still require the full dataset.
References
- ClinicalTrials.gov. A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001). NCT05933577. ClinicalTrials.gov
- Khattak A, Carlino MS, Meniawy T, et al. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study. Journal of Clinical Oncology, 2026. DOI: 10.1200/JCO-26-00835
- Moderna and Merck. Five-year data for intismeran autogene in combination with pembrolizumab in high-risk stage III/IV melanoma following complete resection. June 1, 2026. Merck
- Reuters. Moderna vaccine cuts recurrence and spread of high-risk melanoma, raising new treatment hope. August 19, 2026. Reuters